The estimated Net Worth of Anthony J. Polverino is at least $1.05 million dollars as of 31 August 2021. Dr Polverino owns over 4,900 units of Zymeworks BC Inc stock worth over $439,629 and over the last 7 years he sold ZYME stock worth over $0. In addition, he makes $606,708 as Chief Scientific Officer & Exec. VP of Early Devel. at Zymeworks BC Inc.
Dr has made over 3 trades of the Zymeworks BC Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,900 units of ZYME stock worth $73,500 on 31 August 2021.
The largest trade he's ever made was exercising 27,500 units of Zymeworks BC Inc stock on 12 December 2019 worth over $412,500. On average, Dr trades about 1,939 units every 35 days since 2018. As of 31 August 2021 he still owns at least 36,333 units of Zymeworks BC Inc stock.
You can see the complete history of Dr Polverino stock trades at the bottom of the page.
Dr. Anthony J. Polverino Ph.D. is the Chief Scientific Officer & Exec. VP of Early Devel. at Zymeworks BC Inc.
As the Chief Scientific Officer & Exec. VP of Early Devel. of Zymeworks BC Inc, the total compensation of Dr D at Zymeworks BC Inc is $606,708. There are 1 executives at Zymeworks BC Inc getting paid more, with Dr. Ali Tehrani having the highest compensation of $877,656.
Dr D is 58, he's been the Chief Scientific Officer & Exec. VP of Early Devel. of Zymeworks BC Inc since . There are 2 older and 4 younger executives at Zymeworks BC Inc. The oldest executive at Zymeworks BC Inc is Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D., 71, who is the VP of Intellectual Property.
Anthony's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1 et Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: